Advertisement

Product › Details
Opdivo®
![]() |
Next higher product group | nivolumab |
![]() |
Status | 2014-12-01 registration start |
![]() |
Organisation | Bristol-Myers Squibb Co. (BMS) (NYSE: BMY) |
Group | Bristol-Myers Squibb (BMS) (Group) | |
Organisation 2 | Ono Pharmaceutical Co., Ltd. (TSE: 4528) | |
Group | Ono Pharmaceutical (Group) | |
Thermo Fisher Scientific Inc.. (2/25/16). "Press Release: Thermo Fisher Scientific Declares Quarterly Dividend". Waltham, MA.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on April 15, 2016, to shareholders of record as of March 15, 2016.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
Contact:
Thermo Fisher Scientific Inc.
Media Contact Information:
Ron O’Brien, 781-622-1242
ron.obrien@thermofisher.com
www.thermofisher.com
or
Investor Contact Information:
Ken Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
Record changed: 2020-03-28 |
Advertisement

More documents for Opdivo®
- [1] Biocartis Group N.V.. (3/5/20). "Press Release: Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla MSI test in China". Mechelen....
- [2] ESMO. (9/18/19). "Press Release: Electronic Nose Can Sniff Out Which Lung Cancer Patients Will Respond to Immunotherapy [Annals of Oncology Press Release]"....
- [3] Bristol-Myers Squibb Company. (1/3/19). "Press Release: Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company". New York, NY & Summit, NJ....
- [4] Bavarian Nordic A/S. (7/11/18). "Press Release: Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer". Copenhagen....
- [5] Bavarian Nordic A/S. (3/8/18). "Press Release: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer". Copenhagen....
- [6] Agilent Technologies Inc.. (9/19/17). "Press Release: Agilent Announces Expanded Use of Cancer Diagnostic in the United States. Dako PD-L1 IHC 28-8 PharmDx Approved for Two New Indications". Santa Clara, CA....
- [7] Agilent Technologies Inc.. (6/16/17). "Press Release: Agilent Technologies Announces Expanded Use of Cancer Diagnostic in Europe". Santa Clara, CA....
- [8] Bristol-Myers Squibb Company. (6/2/17). "Press Release: European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platin...
- [9] Transgene S.A.. (4/25/17). "Press Release: Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer". New York, NY & Stras...
- [10] Transgene S.A.. (12/7/16). "Press Release: UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)". Strasbourg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top